Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients
Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...
Prognostic significance of tumor immune microenvironment dynamics in prostate cancer induced by androgen deprivation therapy. Impact of specimen type on digital histopathology-based multimodal ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher ® Prostate RP genomic classifier is uniquely recommended in the 2022 National ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...
Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology “The breadth and depth of Decipher-focused data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results